Vivo Bio Tech Limited has achieved a major milestone by launching a state-of-the-art large animal research facility. The 15,000 sq. ft. facility, co-funded through internal accruals and institutional debt, is equipped to house, breed, and conduct studies on canines, pigs, mini-pigs, sheep, and goats.
This advanced facility has been developed following approval from the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA) and is already operational. It offers a wide range of services, including Pharmacokinetic (PK), Pharmacodynamic (PD), Surgical Studies, and Toxicology Studies, catering to a growing clientele of major pharmaceutical and biopharmaceutical companies.
The addition of this facility enhances Vivo Bio Tech’s existing ecosystem, which includes In-vitro and In-vivo Small Animal Studies, Eco-Toxicology, and Analytical and Bio-analytical services. It positions the company among a select group of Contract Research Organizations (CROs) capable of supporting diverse R&D needs across both large and small animal models.
Vivo Bio Tech aims to further expand its capabilities to serve as a joint discovery partner for global pharmaceutical organizations. Future developments in this area will be shared as they materialize.
